Rapport Therapeutics Inc [RAPP] stock prices are up 3.93% to $28.32 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RAPP shares have gain 12.78% over the last week, with a monthly amount glided 9.22%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rapport Therapeutics Inc [NASDAQ: RAPP] stock has seen the most recent analyst activity on November 19, 2025, when BTIG Research initiated its Buy rating and assigned the stock a price target of $47. Previously, Truist started tracking the stock with Buy rating on September 16, 2025, and set its price target to $44. On August 06, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $31 on the stock. Citizens JMP started tracking the stock assigning a Mkt Outperform rating. TD Cowen initiated its recommendation with a Buy. Stifel started tracking with a Buy rating for this stock on July 02, 2024, and assigned it a price target of $35. In a note dated July 02, 2024, Jefferies initiated a Buy rating and provided a target price of $35 on this stock.
The stock price of Rapport Therapeutics Inc [RAPP] has been fluctuating between $6.43 and $42.27 over the past year. Currently, Wall Street analysts expect the stock to reach $44 within the next 12 months. Rapport Therapeutics Inc [NASDAQ: RAPP] shares were valued at $28.32 at the most recent close of the market. An investor can expect a potential return of 55.37% based on the average RAPP price forecast.
Analyzing the RAPP fundamentals
Gross Profit Margin for this corporation currently stands at -0.19% with Operating Profit Margin at -152.93%, Pretax Profit Margin comes in at -135.69%, and Net Profit Margin reading is -135.69%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.29 and Total Capital is -0.21. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 27.46 points at the first support level, and at 26.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 28.88, and for the 2nd resistance point, it is at 29.45.
Ratios To Look Out For
It’s worth pointing out that Rapport Therapeutics Inc [NASDAQ:RAPP]’s Current Ratio is 36.37. Further, the Quick Ratio stands at 36.37, while the Cash Ratio is 17.56.
Transactions by insiders
Recent insider trading involved Ceesay Abraham, Chief Executive Officer, that happened on Nov 17 ’25 when 5833.0 shares were sold. Chief Executive Officer, Ceesay Abraham completed a deal on Nov 17 ’25 to sell 5083.0 shares. Meanwhile, Chief Scientific Officer Bredt David sold 8500.0 shares on Nov 17 ’25.
